ABCD makes DKA and COVID-19 safety recommendations
Healthcare professionals treating people with Diabetic ketoacidosis (DKA) and COVID-19 must consider additional safety concerns, the National Inpatient Diabetes COVID-19 Response Group has warned.
The organisation, supported by ABCD which represents consultant diabetologists has issued guidelines on its website, reminding clinicians that people with type 1 diabetes who are taking SGLT-2 inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin and Ertuglifozin) are at risk of developing DKA during any intercurrent illness.
But, as there is currently a lack of “high-quality evidence ” relating to DKA and COVID-19, the organisation has said that it believes “clinicians may wish to discuss these medications with their patients and possibly mutually agree to stop SGLT-2 inhibitors and control blood glucose by adjusting insulin doses”.
Dr Umesh Dashora said: “We recommend that people with type 1 diabetes should not be initiated on SGLT-2 inhibitors in addition to insulin until [the] COVID epidemic is over.
“People with type 2 diabetes can continue to take SGLT-2 inhibitor drugs unless they become unwell. If they become unwell for any reason, it is advisable to stop this class of drugs until complete recovery. People with type 2 diabetes who have had DKA once, should not restart these drugs and their diagnosis as well as capacity to secrete endogenous insulin should be reviewed.”
To read the article, click here.
Picture courtesy of HH E